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1. Introduction 
Inflammatory bowel diseases (IBD) are chronic remittent or progressive inflammatory 
conditions that may affect the gastrointestinal tract. Crohn’s disease (CD) and Ulcerative 
colitis (UC) are two main phenotypes of IBD. Their etiopathogenesis has not been elucidated 
but is thought to involve a complex interplay among genetic, environmental, microbial and 
immune response (1). In the last two decade the advances in our knowledge of the 
pathogenesis mechanism underlying chronic inflammation in the gut, together with the 
increase progress in biotechnology have led to the development of a number of biological 
agent that selectively target specific molecules and pathway involve in gut inflammation. 
We briefly review the mechanism of action and the efficacy of biological agent in UC. 
2. Pathogenetic background 
2.2 Genetics factors 
Both types of IBD occur in genetically susceptible individuals. IBD, considered a polygenic 
disorder, is familial in 5-10% and sporadic in the remainder (2). In UC phenotypic 
concordance in monozygotic twins is less frequent (10-20%) than in CD (50-70%), suggesting 
that the environmental factors play a more important role. Genetic studies, including 
genome wide association studies (GWASs) have improved our knowledge on the 
importance of genetic susceptibility in IBD. Interesting GWASs revealed a substantial 
overlap in genetic risk factors between CD and UC (3). However it is possible that this 
similitude is not shared at the level of structurally or functionally relevant polymorphisms. 
However some loci are quite unique for UC or for CD. For example loci related to regulatory 
pathways (IL10) intestinal epithelial cell function (ECM1) and HERC2 appear to be specific 
for UC. A striking outcome of GWASs is that the vast majority of identified loci individually 
confer a modest risk (odds ratios 1.11 and 1.29). The genetic basis for sporadic IBD may be 
due to the cumulative effect of interaction of unknown quantities of potentially thousands of 
common single nucleotide polymorphisms of minor individual biologic impact. 
2.3 Environmental factors 
The discordance of IBD among monozygotic twins and the development of IBD in 
immigrants to high prevalence countries and in countries under going rapid Westernization 
also highlight the importance of environmental factors in disease pathogenesis. Elements 
within a changing environmental that might affect development of the mucosal immune 
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system and the enteric microflora include improved hygiene, consummation of sterile and 
no fermented foods, vaccination and age at first exposure to intestinal pathogens (4). The 
effects of poorly hygiene at early childhood are diverse; in some situation poor hygiene can 
lead to increase pathogenic infections, but in others it results in a higher exposure to 
harmless microorganisms and priming of the regulatory immune system, thus lowering the 
risk for development of IBD. Other environmental factors could affect the disease phenotype 
is the cigarette smoking that has an opposite effect on the outcome of each form of IBD, most 
reports have shown that no smoking is a feature of patients in UC, whereas smoking is a 
feature of CD patients (5-6). A cigarette smoking has been shown to affect cellular ad 
humoral immunity (7-8), and to increase mucous production (9). Results from in vivo 
studies have shown that nicotine also has an inhibitory effect on Th2 function that 
predominates in UC. 
2.4 Microbial flora 
The contest of the intestinal lumen plays a central role in gut homeostasis. The 
gastrointestinal tract harbors more than 10 14 microorganisms of more than 1000 species. 
Most belong to two different phyla that account for the majority of gram-negative bacteria 
(bacterioides) and gram-positive bacteria (Firmicutes). Collectively, the microbiota carries 
out many physiological functions important in mammalian biology. In fact, the microbiota is 
required for the development and differentiation of local and systemic immune and 
nonimmune components (10). Systemic immune responses are also impaired in germ-free 
mice, including the development of adequate Treg responses leading to increased systemic 
autoimmunity (11), which may have implication for the development of extraintestinal 
manifestation in IBD. Luminal bacteria appear to provide the stimulus for immuno-
inflammatory responses leading to mucosal injury. In IBD mucosal production of IgG 
antibodies against intestinal bacteria is highly increased, and mucosal defense relies on both 
IgG mediated responses within the tissue and hyperactivated lymphocytes in the lamina 
propria reacting against bacterial antigens. These combined events result in inflammation 
and tissue injury. The altered immune response is not specifically addressed or polarized 
toward a single group of potential pathogens, but involves a large and undefined number of 
commensal species belonging to the common enteric flora. Several factors may contribute to 
the abnormal reactivity of the mucosal immune system against enteric bacteria, and these 
include genetic susceptibility, a defect in mucosal barrier function, and a microbial 
imbalance in the gut ecosystem (1). 
Several studies have shown that the composition of the fecal microbiota differs between 
subjects with IBD and healthy controls. The reported differences are variable and not always 
consistent among the various studies. However, molecular studies show that a substantial 
proportion of fecal bacteria (up to 30%–40% of dominant species) in patients with active IBD 
belong to phylogenetic groups that are unusual in healthy subjects (12).  
2.5 Immuno-inflammatory factors 
This complex interaction of genetic, environment and microbial factors culminates in a 
sustained activation of the mucosal immune and non immune response resulting in active 
chronic inflammation and tissue damage (1). 
In the healthy gut the mucosal immune system maintains a balance between pro- and anti-
inflammatory factors, thereby allowing an effective defense against luminal pathogens 
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while simultaneously preventing an overactive immune response. In IBD, this balance is 
altered with a shift toward a proinflammatory state owing to a deregulated immune system 
with a complex interplay between effect and regulatory T cells and immunosuppressive and 
proinflammatory cytokines (13). 
3. Definition of biologic therapy 
The promise of biologic therapy is the direct translation of the knowledge of basic 
mechanisms of disease into therapies of enhanced specificity. Biologic therapies encompass 
agents of diverse modes of action. Biologic therapies may be considered to fall under five 
broad categories: (a) native biologic preparations and isolates, included proteins isolated 
from blood or serum, such as clotting factors or immune globulins, as well as classic 
vaccines incorporating live, attenuated, or killed microorganisms, or their isolated subunits; 
(b) recombinant peptides or proteins, many diverse classes of peptides and proteins with the 
shared feature of having been produced in recombinant cell-based systems, such as bacteria, 
yeast, or mammalian cells in culture. Most important are recombinant cytokines, cytokine 
receptor antagonists, and soluble receptors for cytokines and other relevant ligands; (c) 
antibody-based therapies, monoclonal antibodies may be used for therapeutic purposes, but 
their utility may be limited by the development of humoral immunity against these non-
native proteins; (d) nucleic acid-based therapies, the most promising agents of this type are 
antisense oligonucleotides. These agents consist of synthetic oligonucleotides of single- 
stranded DNA bearing a sequence complementary to that of a targeted mRNA species. (e) 
Cell and gene therapies, include techniques that may alter autologous or donor cell 
populations. This category may include the treatment of targeted cells with various factors 
or cytokines ex vivo, or the insertion or deletion of targeted genes in isolated cells ex vivo 
followed by reintroduction into the host. Alternatively, genetic manipulation may be 
accomplished by means of viral or plasmid vectors in vivo (14). 
4. New biologic drugs for UC 
4.1 Blockade of T-cell activation 
T cell activation requires two signals. The first signal is mediated by the interaction of the T 
cell receptor complex, with includes CD4 and CD3, with the antigenic peptides presented by 
major histocompatibility complex molecules on the surface of antigen presenting cells; the 
second signals (the costimulatory signals), is antigen non specific and is provided by the 
interaction between costimulatory molecules expressed on the membrane of antigen 
presenting cells and the T cell, activation of T cell without costimulatory signals leads to T 
cell anergy, deletion or immune tolerance. 
4.1.1 Anti CD4+ antibodies 
Anti CD4 antibodies have been used in a variety of autoimmune disease, and have been 
tested in CD and UC. A CD4 depleting antibody (cM-T412) was tested in one open label 
study in UC patients achieved clinical and endoscopic improvement/remission after a 
period of treatment ranging from seven to eleven days (15). In another three open trials a 
CD4 no depleting antibodies (MAX.16H5 and B-F5) were administered to nine UC patients 
with active disease; of the nine patients, five achieved remission. Thus, CD4 depleting 
antibodies seem to be more effective than no depleting antibodies therapy. However, this 
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specific treatment was most associated with a significant decrease in CD4 cells, and because 
of concerns of CD4 lynmphopenia no further studies have been performed (16,17). 
4.1.2 Anti CD3+ antibodies 
Visilizumab (HuM291) is a non-fragment crystallized region (FcR) binding anti CD3 
monoclonal antibody directed against invariant CD3ε chain of the T cell receptor; this 
compound was studied in patients with severe refractory UC. In an open label phase I/II 
trials, eight patients received a 15 μg/Kg intravenous bolus dose of Visilizumab on two 
consecutive days and two others received 10 μg/Kg. Remission was achieved after 1 month 
in seven of the eight patients in the 15 μg/Kg group and after 15 days in all patients in the 
10 μg/Kg group. All 8 patients in the high dose group showed improvement based on 
endoscopic assessment. Endoscopic lesions were absent or only mild in six out of eight 
patients, and most patients in remission managed to fully taper off their concomitant 
steroids treatment. An extension of these original trials comprised a total of 24 patients 
treated with 10 μg/Kg Visilizumab. On day 30 clinical improvement, remission rate and 
endoscopic remission were observed in 84%, 66% and 44% of patients. After one year, ten 
out of 22 patients did not require surgical or medical salvage therapy and colectomies were 
performed for intractable colitis in seven patients during follow up evaluation with a 
median time to colectomy of 160 days (18). However a phase III randomized double blind 
placebo controlled multicenter study of Visilizumab in patients with intravenously steroids 
refractory ulcerative colitis was withdrawn and the Visilizumab was terminated because an 
interim analysis showed no difference in colectomy rates from Visilizumab versus placebo 
(19). 
4.1.3 Anti IL2-receptor (CD25) 
CD25 is a membrane receptor expressed by activated T lymphocytes. IL-2 is a cytokine 
produced by T cells that induced lymphocyte proliferation and clonally expansion. 
Cyclosporine, a calcineurin inhibitor, which inhibits IL-2, is effective for the treatment of 
severely active ulcerative colitis; therefore it was proposed that blocking IL-2 would be an 
effective therapy for ulcerative colitis (20). 
Daclizumab (Zanapax, Protein Designed Labs) is a recombinant humanized IgG1 
monoclonal antibody to IL-2 receptor, witch blocks the binding of IL-2 to the receptor 
(CD25). In an open label pilot trial, ten patients were included and were given two 
intravenous doses (1 mg/Kg) with 4 weeks interval between doses. Promising response 
rates at 8 weeks suggested that it was beneficial for patient with active UC (21). 
Subsequently a randomized double blind placebo control trial was conduced to evaluate the 
efficacy of induction therapy with Daclizumab in active UC patients. One hundred and nine 
patients with moderate UC were assigned randomly to groups that were given 
intravenously 1 mg/Kg dose at weeks 0 and 4; 2 mg/Kg dose at weeks 0,2,4 and 6 
compared with patients that received placebo. At week 8 remissions and responses 
respectively were observed in 2% and 25% of patients receiving Daclizumb 1 mg/Kg and 
7% and 33% of patients receiving 2 mg/Kg compared with 10% and 44% of those received 
placebo. Daclizumab failed to show any efficacy in active UC (22). 
Basilizumab (Simulect, Novartis), a chimeric anti CD25 monoclonal IgG1 antibody was 
evaluated only in open label pilot trial. Fifteen patients received Basilizumab in addition to 
their standard steroid treatment to evaluate the efficacy of treatment as a steroids sensitizing 
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agent in steroid-resistant UC. Eighty per cent of patients achieved remission within 6 weeks 
(23). Basilizumab was evaluated only in open label trials and the data might show efficacy 
but larger placebo controlled trials are needed. 
4.1.4 Abadacept 
Abatacept modulates naïve T-cell activation and downstream cytokine production. It is a 
fully human, soluble fusion protein, which consists of the extracellular domain of human 
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) linked to the Fc portion of human 
immunoglobulin G1. The CTLA-4 portion of the molecule interrupts the CD80/ CD86:CD28 
costimulatory signal, mimicking a native homoeostatic mechanism of T-cell down 
regulation. It is effective in treating patients with rheumatoid arthritis and phase III trials 
are underway to test its effects in patients with UC and CD. 
4.2 Inflammatory cytokines 
4.2.1 Anti tumor necrosis factors 
TNF-ǂ is a proinflammatory cytokine that has a critical role in the amplification of mucosal 
inflammation in IBD. TNF-ǂ acts as transmembrane or soluble proteins by transducing 
signals ranging from cellular activation and proliferation to cytotoxicity and apoptosis 
through two distinct TNF receptors (TNFR1 and TNFR2). The currently most efficacious 
treatment for IBD is anti-TNF antibodies. Actually three anti TNF molecules are studied to 
treat UC. 
Infliximab is a monoclonal chimeric antibody, targeting TNF-ǂ composed of a human 
constant region IgG1K light chain, accounting for approximately 75% of antibody, linked to 
a mouse variable region (25%). Initially Infliximab did not seem to have much therapeutic 
effect on UC. Two small pilot trials showed disappointing results for the drug in the 
treatment of refractory UC (24-25). Recently a new role of Infliximab in the treatment of UC 
has been offered by two large placebo controlled trials ACT1 and ACT2 (26). In the ACT1 
364 patients with active UC with endoscopic evidence of moderate-severe were randomly 
assigned to receive placebo or Infliximab 5 mg/Kg or 10 mg/Kg at weeks 0, 2, 6 and every 8 
weeks through to week 46. At week 8 38,8% patients receiving 5 mg/kg dose and 32% of 
patients receiving the higher dose achieved remission comparing 14.9% of patients receiving 
placebo. This difference in remission rates was maintained at week 30 (33.9% 5 mg/kg, 
36.9% 10 mg/kg versus 15.7% placebo). Mucosal healing was achieved at weeks 8 and 30 
respectively in 62% and 50.4% in the lower dose group, in 59% and 49.2% in the higher dose, 
and in 33.9% and 24.8% in the placebo group. In the ACT2 study 364 UC patients, refractory 
to at least one standard therapy were randomly assigned to receive placebo or Infliximab 5 
mg/Kg or 10 mg/Kg at weeks 0, 2, 6, 14 and 22. Clinical remission evaluated at week 8 and 
30 were respectively 33.9% and 25.6% in 5 mg/kg Infliximab group, 27.5% and 35.8% in 10 
mg/Kg Infliximab group versus 5.7% and 10.6% in the placebo group. Mucosal healing was 
achieved at weeks 8 and 30 respectively in 60.3% and 46.3% in the lower dose group, in 
61.7% and 56.7% in the high dose group, and in 30.9% and 30.1% in the placebo group. In 
both trials Infliximab was well tolerated and induces and maintains clinical response and 
mucosal healing in moderate to severe UC patients.  
Adalimumab is a fully human IgG1 monoclonal antibody to TNF-ǂ that is administrated 
subcutaneously and easily can be self administrated every 2 weeks. In the first randomized 
double-blind controlled trial of efficacy and safety of Adalimumab for the induction of 
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clinical remission in 390 patients with moderate to severe active UC (27). Patients were 
administrated either with placebo or Adalimumab every two weeks for a total of four doses 
over a 6 week period. Adalimumab was administrated according to one of the following 
dosage scheduled: 1) 160 mg at week 0, 80 mg at week 2 and 40 mg at week 4 and 6; 2) 80 
mg at week 0 and 40 mg at weeks 2,4, and 6. At week 8, 18.5% of patients received 
Adalimumab 160/80/40 mg had achieved remission (p=0.031 verso placebo), which was 
significantly greater proportion than those patients received Adalimumab 80/40 mg 
(10%)(0.833 verso placebo) or placebo (9.2%). No significant differences were observed in 
the rate of serious adverse events. Adalimumab was therefore well tolerated and effectively 
induced remission in approximately one-fifth of patients with moderate to severe active UC. 
In this trial numerous secondary end points were also positive for the higher dose of 
Adalimumab. Despite the relative poor comparative performance of Adalimumab that, 
perhaps, suggests inadeguate dosing in the UC trials, several open-label series have 
reported benefits from Adalimumab in UC patients who responded, but became intolerant 
of Infliximab. (28,29). 
RDP58 is a novel anti-inflammatory decapeptide able to clock TNF production at a post 
transcriptional step (30) and also inhibits production of IFN-Ǆ, IL-2 and IL-12. RDP58 has 
been shown to be effective in murine and primate models of colitis (31, 32). In a phase II 
study 127 patients with mild moderate UC were randomly assigned to receive placebo or an 
oral solution of RDP58 at 100, 200 or 300 mg daily for 28 days. Clinical remission was 
achieved in 72% of patients in the 300 mg group, 70% of patients in the 200 mg group and 
29% in the lower dose exhalation versus the placebo group. There were any differences in 
adverse events among treatments group compared to placebo group (33).  
4.2.2 Immunomodulators: reconbinant human Interferon α and β 
IFNs ǂ and ǃ are produced by virally infected cells and inhibit viral replication within host 
cells, activate natural killer cells and macrophage, and increase antigen presentation to 
lymphocytes. IFNs ǂ and ǃ have been investigated in UC with no success. In a multicenter 
double blind placebo controlled trial, patients with moderate active UC were randomized to 
receive two doses of INF-ǃ-1a (44 and 66 mcg subcutaneously 3 times weekly for 8 weeks) 
versus placebo. No differences between INF-ǃ-1a and placebo were observed at 12 weeks 
(34). 
4.3 Anti inflammatory cytokines 
IL-10 is an anti-inflammatory cytokine produced by T cells, B cells and monocyte activated 
lipopolysaccharides. When the body is presented with an antigen, IL-10 inhibits the 
production of IL-1ǂ, IL-6 and TNF-ǂ. Thus, it contributes to down regulation of acute 
inflammatory responses (13) In animal models, IL-10 maintains immune homeostasis in the 
gut and may play a role in the treatment of IBD (35). A phase II placebo-controlled dose 
response trial with recombinant IL-10 (rHuIL-10) failed to show a beneficial effect in 94 UC 
patients with mild to severe active disease (36). Development of systemic administration of 
rHuIL-10 for IBD was discontinued because of lack of efficacy in controlled trials but other 
animal studies showed that local administration of IL-10 to the colon via genetically 
engineered Lactococcus lactis bacteria that are administered orally allows for the achievement 
of high colonic mucosal concentration of IL-10, resulting potentially in increased efficacy. It 
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is possible that this approach to IL-10 therapy will be an alternative therapeutic approach 
for IBD (37). 
4.4 Selective adhesion molecule inhibitors 
Leukocyte adhesion in high endothelial venules of the gut is a multistep process. Fast 
moving immune cells are first slowed down by interaction of selectins and non-activated 
integrins with their respective ligands expressed by endothelial cells. This causes tethering 
and rolling of leukocytes close to the endothelial surface. Chemokines secreted from sites of 
inflammation diffuse through the endothelial layer, bind to chemokine receptors and 
activate integrins. Firm adhesion is the last step before leukocyte diapedesis through 
endothelial pores and results from strong binding between activated ǂ4ǃ7 integrins with 
their ligand, mucosal addressing cellular adhesion molecule-1 (38). Agent that block 
interaction between adhesion molecules on circulating immune cells and their endothelial 
cell receptors wound be expected to decrease the migration of these cells through the 
endothelium, thereby decrease chronic inflammation (39). 
Natalizumab is a recombinant humanized IgG4 monoclonal antibody to ǂ4 integrin that 
block adhesion and subsequent leukocyte migration into the gut. It inhibits both 
ǂ4ǃ7integrin/MAdCAM-1 interaction and ǂ4ǃ7/VCAM-1 binding. Natalizumab 3mg/Kg 
single intravenous infusion has also demonstrated some evidence of clinical benefit at two 
weeks post infusion in an uncontrolled study in 10 patients with active UC. Five out of 10 
patients achieved a good clinical response at 2 weeks and one more patients at 4 weeks, 
defined by a Powell-Tuck score of < 5 (40). Natalizumab was withdrawn voluntarily from 
the marked in February 2005 for safety evaluation after one fatal and one non fatal case of 
progressive multifocal leukoencephalopathy (PML) occurred in the group of 1869 patients 
who were treated with Natalizumab in combination with Interferon-ǃ-1a over a 2 years 
period for treatment of multiple sclerosis. Although the 3 case of PML, a review by Youry et 
al of more than 3000 patients who have received Natalizumab for multiple sclerosis, CD or 
rheumatoid arthritis suggested a risk of PML of 1/1000 patients treated with Natalizumab 
for a mean duration of 17.9 months (41). Natalizumab was reintroduced to the market for 
multiple sclerosis and CD in the United States. 
Vedolizumab (formerly MLN-02 and LDP-02) is a humanized anti- ǂ4ǃ7-integrin antibody 
MLN-0002, that selectively inhibits leukocyte adhesion in the gastrointestinal mucosa. 
Therefore this compound is being developed only in IBD. A fase I/II, double blind, place 
controlled, ascending dose trial examined the safety and pharmacology of MLN-0002 in 28 
UC patients with moderate severe disease (42). Patients received a single dose of 0.15 
mg/kg s.c., a single dose of 0.15, 0.50, or 2.0 mg/kg e.v. or placebo. MLN_0002 appeared to 
be a generally well-tolerated and effective therapy for active UC. Four years later a 
multicenter double blind placebo controlled trial was performing involving 181 patients 
with active UC confirmed efficacy of MLN-0002 in the treatment of active disease. Patients 
were treated with 2 intravenous dose, 28 days apart, of 0.5 mg/kg or 2.0 mg/Kg of MLN-
0002 or placebo. At week 6, clinical remission rates were 33%, 32% and 14% in the groups 
given 0.5 mg/Kg of MLN-0002, 2.0 mg/kg of MLN-0002 and placebo respectively; 
percentage of patients who improved by at least 3 points on UC clinical score were 
respectively 66%, 53% and 33%. Remission was observed by endoscopy in 28% in the lower 
dose of MLN-0002, in 12% in the higher dose group compared with 8% in the placebo group 
(43). 
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The interaction of lymphocyte-associated ǂ1ǃ2-integrin and its ligand ICAM-1 (Intracellular 
adhesion molecule-1) is important for the recruitment of leukocytes to inflammatory sites. 
Alicaforsen (ISIS 2302) is a 20-base phosohorothioate antisense oligodeoxynucleotide. It is 
designed to hybridize to a 3’ untranslated region of human ICAM-1 messenger ribonucleic 
acid (mRNA). The heterodimer formed is cleaved by ubiquitous ribonuclease H, resulting in 
a reduction in ICAM-1 protein expression (44). Initial positive results in CD patients 
reported in a pilot study were not confirmed in two subsequent placebo controlled trial (45-
47). Instead in a placebo controlled trial with ISIS 2302 in enema formulation showed 
significant improvement in 40 patients with distal UC (48). In a phase 2, dose-ranging, 
double-blind, placebo-controlled study, 112 patients with mild-moderate left-sided UC 
received one of four ISIS 2302 enema regimens or placebo daily for 6 weeks (49). While there 
were no significant differences between treatment or placebo in terms of DAI at week 6, 
there was a prolonged reduction in the mean percentage DAI relative to baseline from week 
18 (51% versus 18% p=0.04) to week 30 (50% versus 11% p=0.03) in the 240 mg ISIS 2302 
group compared with placebo. 
Monoclonal antibodies to Madcam-1 and integrin ǃ7 subunit (50) are currently being tested 
in clinical trials..  
4.5 Growth factors 
Epithelial growth factors are naturally occurring proteins capable of stimulating cellular 
growth, proliferation and differentiation. A potent mitogenic peptide produced by 
salivary glands, epidermal growth factors (EGF) and keratinocyte growth factor (KGF) 
may play an important role in IBD for their potential use to restore mucosal integrity (51). 
In UC the inflammation is confined to the mucosa and epithelial cell damage is an 
important feature. 
Repifermin (KGF-2) has been shown to reduce inflammation in animal models of colitis 
(52-54). The effect of Repifermin were studied in a phase II, placebo controlled trial in 88 
patients with active UC. Patients were randomized to receive treatment for five 
consecutive days with intravenous repifermin at a dose of 1, 5, 10, 25 or 50 lg/kg, or 
placebo. Intravenous repifermin at a dose of 1–50 μg/kg was very well tolerated, but 
there was no evidence that repifermin was effective for the treatment of active UC at these 
doses (55). 
In randomized, double-blind clinical trial conducted, 12 patients with mild-to-moderate 
left-sided UC received daily enemas of 5 μg of EGF in 100 ml of an inert carrier and 12 
patients received daily enemas with carrier alone for 14 days, all patients also began to 
receive 1.2 gr of oral mesalamine per day or had their dose increased by 1.2 gr per day. 
After two weeks, 10 of the 12 patients treated with EGF enemas were in remission, as 
compared with 1 of 12 in the control group (83 percent vs. 8 percent, P<0.001). At the 2-
week assessment, disease-activity score, endoscopic score and histology score were all 
significantly better in the EGF group than in the placebo group (p<0.01 for all 
comparisons), and this benefit was maintained at 4 and at 12 weeks. This study provides 
preliminary data suggesting that EGF enemas are an effective treatment for active left-
sided UC (56). Further studies are warranted, but the safety of therapy stimulating EGF in 
UC is most importantly because it up regulates the expression of protoncogen in patients 
with known colon cancer risk. 
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5. Conclusion: The state of art biologic agent in UC 
Over the last two decades, advances in bio-technology together with the increasing 
knowledge about the pathogenesis of IBD and the mechanism driving the uncontrolled 
inflammation led to discovery new targets for a large number of biological agents. The 
improved understanding of pathogenic mechanisms and the basis of heterogeneity within 
the disease group should lead to different therapeutic approaches for various disease 
phenotypes and eventually to personalize treatment. The benefits for anti-TNF therapy in 
UC have opened the door of clinical practice for additional anti-TNF or for agents with 
alternative targets. Early studies have suggested potential benefits of inhibiting adhesion 
molecules such as α4β7 integrins or inhibition of ICAM-1; on the other hand studies 
evaluating therapies targeting T cell activation have been disappointing. Finally, given that 
the efficacy, short-term and long term for the newer biological therapeutics are either 
limited or remain to be proven on a large number of patients, the use of such agents in 
patients remains to be estimated and tailored on the single patient. 
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